60. Aplastic anemia Clinical trials / Disease details


Clinical trials : 235 Drugs : 381 - (DrugBank : 83) / Drug target genes : 44 - Drug target pathways : 160

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05088655
(ClinicalTrials.gov)
June 25, 202112/10/2021A Bioequivalence Study of Hetrombopag in Healthy SubjectsBioequivalence Study of Different Formulations of Hetrombopag Olamine Tablets in Healthy SubjectsSever Aplastic AnaemiaDrug: Hetrombopag Olamine TabletJiangsu HengRui Medicine Co., Ltd.NULLRecruiting18 Years45 YearsAll57Phase 1China
2NCT05088642
(ClinicalTrials.gov)
September 28, 202012/10/2021A Trial of Hetrombopag in Healthy and Hepatic Impairment SubjectsA Phase I Clinical Study Evaluating the Pharmacokinetics and Safety of Hetrombopag Olamine Tablets in Subjects With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Hepatic FunctionSever Aplastic AnaemiaDrug: Hetrombopag Olamine TabletJiangsu HengRui Medicine Co., Ltd.NULLCompleted18 Years65 YearsAll24Phase 1China
3NCT05088174
(ClinicalTrials.gov)
September 3, 202012/10/2021A Trial of Hetrombopag in Healthy SubjectsA Single-Center, Single-Arm, Open-Label, Self-Controlled, Drug-Drug Interaction Study of Hetrombopag Olamine and Ciclosporin in Healthy SubjectsSever Aplastic AnaemiaDrug: Hetrombopag Olamine Tablet;Ciclosporin Soft CapsuleJiangsu HengRui Medicine Co., Ltd.NULLCompleted18 Years65 YearsAll26Phase 1China
4NCT04961710
(ClinicalTrials.gov)
September 19, 201912/7/2021Extension Study of Hetrombopag in Severe Aplastic AnemiaExtension Study of Hetrombopag Olamine in Patients With Treatment-naive Severe Aplastic AnemiaTreatment-naive Severe Aplastic AnemiaDrug: Hetrombopag Olamine;Drug: PlaceboJiangsu HengRui Medicine Co., Ltd.NULLRecruiting15 Years75 YearsAll180Phase 3China
5NCT03825744
(ClinicalTrials.gov)
March 5, 201930/1/2019Hetrombopag or Placebo in Treatment-Naive Severe Aplastic AnemiaA Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic AnemiaSevere Aplastic AnemiaDrug: Hetrombopag Olamine+Standard Therapy;Drug: Placebo+Standard TherapyJiangsu HengRui Medicine Co., Ltd.NULLRecruiting15 Years75 YearsAll180Phase 3China
6NCT03557099
(ClinicalTrials.gov)
June 20, 20183/6/2018A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) PatientA Multicentre, Open-label, Single-arm, Phase II Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Severe Aplastic AnemiaSevere Aplastic AnemiaDrug: Hetrombopag OlamineJiangsu HengRui Medicine Co., Ltd.NULLRecruiting18 YearsN/AAll55Phase 1/Phase 2China